Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Sanofi ADR(SNY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SNY
10/28/2026: SNY (1-star) is currently NOT-A-BUY. Pass it for now.
Sanofi is a leading global healthcare company focused on specialty medicines and vaccines. Its investment story centers on the success of core growth drivers like the immunology drug Dupixent, complemented by a stable, high-barrier-to-entry vaccine franchise. While the firm benefits from strong operational margins and a steady dividend, it faces risks related to patent expirations in its legacy general medicine division and intense competition from GLP-1 drug leaders. Sanofi is generally well-suited for value and income-oriented investors seeking defensive exposure to the pharmaceutical sector. Key developments to monitor include the progress of its R&D pipeline and regulatory changes impacting drug pricing.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers moderate growth prospects through its pipeline rather than explosive expansion. |
| Momentum investor | Weak fit | This is a stable, large-cap pharmaceutical stock often characterized by lower volatility than momentum favorites. |
| Value investor | Strong fit | Sanofi's valuation is often reasonable relative to its earnings and dividend yield profile. |
| Dividend investor | Strong fit | The company maintains a reliable dividend history suitable for income-seeking portfolios. |
| Low-risk investor | Strong fit | As a large-cap pharmaceutical player, it offers defensive characteristics during market volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The stock is generally less reactive to short-term market swings compared to growth-oriented sectors. |
| Valuation risk | Medium | Market pricing depends heavily on the continued success of the Dupixent pipeline and R&D execution. |
| Competition risk (Pharmaceutical) | High | The intense battle for market share in immunology and diabetes poses a significant threat to long-term margins. |
| Business quality | Strong | Sanofi possesses a robust global infrastructure and established R&D capabilities. |
| Dividend income | Medium / high | Dividend sustainability remains a key pillar of the investment thesis. |
| Execution risk | Medium | The company's future hinges on the successful clinical trial outcomes and regulatory approval of its new drug pipeline. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -20.53% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 100.37B USD | Price to earnings Ratio 22.05 | 1Y Target Price 53.61 |
Price to earnings Ratio 22.05 | 1Y Target Price 53.61 | ||
Volume (30-day avg) 3.4M shares | Beta 0.28 | 52 Weeks Range 39.07 - 49.91 | Updated Date 10/28/2026 |
52 Weeks Range 39.07 - 49.91 | Updated Date 10/28/2026 | ||
Dividends yield (FY) 9.86% | Basic EPS (TTM) 1.9 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Specialty Care | Includes biologic drugs like Dupixent targeting immunology and rare diseases. | This is the primary growth engine for the company. |
| Vaccines | Global supply of influenza, polio, and meningitis vaccines. | A steady, recurring revenue source with strong market barriers. |
| General Medicines | Established products for diabetes and cardiovascular health. | Provides stable cash flow but faces long-term growth challenges. |
| Geography | Revenue distribution across the US, Europe, and emerging markets. | The US remains a critical market for high-margin specialty drug sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-30 | When Before Market | Estimate 1.63 | Actual - |
Profitability
Profit Margin 8.09% | Operating Margin (TTM) 21.03% |
Management Effectiveness
Return on Assets (TTM) 5.09% | Return on Equity (TTM) 5.71% |
Valuation
Trailing PE 22.05 | Forward PE 8.85 | Enterprise Value 119.85B | Price to Sales(TTM) 2.05 |
Enterprise Value 119.85B | Price to Sales(TTM) 2.05 | ||
Enterprise Value to Revenue 2.18 | Enterprise Value to EBITDA 12.92 | Shares Outstanding 2.40B | Shares Floating 2.16B |
Shares Outstanding 2.40B | Shares Floating 2.16B | ||
Percent Insiders - | Percent Institutions 8 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.